Another clinical trial (NCT02954523, phase I/II) evaluated the effects of the third-generation EGFR-TKI, osimertinib in combination with dasatinib, in EGFR mutant NSCLC patients who developed resistance to the first-generation EGFR-TKIs and assessed serum biomarkers to monitor clinical outcomes upon Src inhibitor treatments. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.